KDM5B is highly expressed in AML patients. (A) Expression levels of KDM5B in HDs (n = 20) and AML patients (n = 698). Data were analyzed from the published GSE114868 data set. (B) Expression levels of KDM5B in normal (HDs, n = 76), AML patients with different types of chromosome rearrangements, and patients with MDS (from A.K to MDS, n = 48, 28, 351, 40, 37, 206, respectively). Data were analyzed from the published GSE13159 data set. (A.K) Aberrant karyotype, (N.K) normal karyotype. (C) Expression levels of KDM5B in LSC (CD34+ CD38−) and corresponding non-LSC cells (CD34−) (n = 20). Data were analyzed from the published GSE63270 data set. (D) The mRNA levels of KDM5B were examined in PBMCs from HD monocytes (n = 10) and CD11b+ (n = 6), as well as from AML patients (n = 15). The levels were determined by real-time quantitative PCR (RT-qPCR) and normalized by Actb. (E) The protein level of KDM5B in AML patients (n = 6) and HDs (n = 6) were examined by western blotting. (*) P < 0.05, (**) P < 0.01, and (***) P < 0.001, by Student's t-test.
